Biotech entity
Every one of those 2 sits in a single category, pharma. Collegium is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 8 original sources each against 3.6 for the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Collegium is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 8 original sources each against 3.6 for the same window. The 5 average consequence score is below the beat benchmark of 6 in the same window. Lantheus appears in 2 tracked Biotech stories published from February 25, 2026 through February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 34 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lantheus. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Lantheus is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
